Explore Oxidative Stress Regulating Therapy with Risuteganib in Dry-AMD

Time: 4:15 pm
day: Day One


  • A Look a pre-clinical studies with risuteganib, a synthetic RGD-class oligopeptide oxidative stress regulator, suggested to protect human RPE cells against oxidative stress-associated cellular dysfunction
  • Learn how collectively, preclinical studies have indicated the retinal cytoprotective, anti-inflammatory, mitochondrial stabilization and antiangiogenic properties of risuteganib in in vitro and in vivo models
  • Examine how in a Phase 2 clinical trial evaluating risuteganib compared to sham, risuteganib met its primary endpoint of proportion of patients gaining >8 ETDRS letters in patients with less advanced dry AMD (48% vs 7%, p=0.013), and had a good safety profile
  • Understand how a larger Phase 2b/3 study is planned to confirm the Phase 2
    study’s findings